Comorbidities in patients with uterine adenosarcoma. A single-center case series of 12 patients

Abstract

Abstract Background Uterine adenosarcoma is a rare low-grade tumor that commonly affects elderly women and is associated with a generally good, although sometimes poor, prognosis. This study investigates the effect of comorbidities in old patients with uterine adenosarcoma. Methods A review of patients who had been diagnosed with uterine adenosarcoma at our institution between 2010 and 2020 was conducted. All patients underwent a specialist pathological review and were re-staged according to the International Federation of Gynecology and Obstetrics 2009 criteria. Patient demographics, staging, histologic features, primary and adjuvant therapy, disease recurrence, and survival time were collected. Results Twelve patients with confirmed uterine adenosarcomas were identified. Their mean age at diagnosis was 58.3 years (range, 31–83 years). Eight patients had pre-existing chronic diseases at the time of diagnosis. All 12 patients underwent surgical therapy. Of these, 10 (83.3%) were stage I, 1 (8.3%) was stage II, and 1 (8.3%) was stage III. Postoperative adjuvant therapies included chemotherapy (n = 1), radiation (n = 1), or no further therapy (n = 10). The mean follow-up duration was 39.2 months (range, 7–104 months). The recurrence and mortality rates were 16.7% (2/12) and 41.7% (5/12), respectively. Five recurrence-free patients died of comorbidities. The mean postoperative survival of these 5 patients was 22.6 months. The remaining seven patients were free of recurrence at the time of this report. Conclusions Comorbidities with age is a significant factor leading to poor prognosis in uterine adenosarcomas. Greater attention should be paid to elderly patients with comorbidities. Targeted interventions, including multi-professional management, tailored assessment, and follow-up, may contribute to improved well-being.